These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

547 related articles for article (PubMed ID: 29644460)

  • 1. Phase II study of cisplatin/pemetrexed combined with bevacizumab followed by pemetrexed/bevacizumab maintenance therapy in patients with EGFR-wild advanced non-squamous non-small cell lung cancer.
    Fukushima T; Wakatsuki Y; Kobayashi T; Sonehara K; Tateishi K; Yamamoto M; Masubuchi T; Yoshiike F; Hirai K; Hachiya T; Koizumi T
    Cancer Chemother Pharmacol; 2018 Jun; 81(6):1043-1050. PubMed ID: 29644460
    [TBL] [Abstract][Full Text] [Related]  

  • 2. A phase II study of carboplatin, pemetrexed, and bevacizumab followed by erlotinib and bevacizumab maintenance for non-squamous non-small cell lung cancer with wild-type EGFR (HOT1101).
    Takashina T; Asahina H; Oizumi S; Yamada N; Harada M; Takamura K; Yokouchi H; Harada T; Honjo O; Ogi T; Morikawa N; Kinoshita I; Honda R; Nakano K; Kanazawa K; Amano T; Dosaka-Akita H; Isobe H; Nishimura M;
    Int J Clin Oncol; 2018 Dec; 23(6):1060-1069. PubMed ID: 30027464
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Multicenter phase II study on cisplatin, pemetrexed, and bevacizumab followed by maintenance with pemetrexed and bevacizumab for patients with advanced or recurrent nonsquamous non-small cell lung cancer: MAP study.
    Tsutani Y; Miyata Y; Masuda T; Fujitaka K; Doi M; Awaya Y; Kuyama S; Kitaguchi S; Ueda K; Hattori N; Okada M
    BMC Cancer; 2018 Dec; 18(1):1231. PubMed ID: 30526545
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Phase1 study of cisplatin plus pemetrexed with erlotinib and bevacizumab for chemotherapy-naïve advanced non-squamous non-small cell lung cancer with EGFR mutations.
    Tamiya M; Tamiya A; Shiroyama T; Takeoka S; Naito Y; Omachi N; Kimura Y; Morishita N; Suzuki H; Okamoto N; Okishio K; Kawaguchi T; Atagi S; Hirashima T
    Invest New Drugs; 2018 Aug; 36(4):608-614. PubMed ID: 29101518
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Switch maintenance therapy with docetaxel and bevacizumab after induction therapy with cisplatin, pemetrexed, and bevacizumab in advanced non-squamous non-small cell lung cancer: a phase II study.
    Nishimoto K; Karayama M; Inui N; Yasui H; Hozumi H; Suzuki Y; Furuhashi K; Fujisawa T; Enomoto N; Nakamura Y; Inami N; Matsuura S; Kaida Y; Matsui T; Asada K; Matsuda H; Fujii M; Toyoshima M; Imokawa S; Suda T
    Med Oncol; 2018 Jun; 35(7):108. PubMed ID: 29909581
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Maintenance therapy with pemetrexed plus best supportive care versus placebo plus best supportive care after induction therapy with pemetrexed plus cisplatin for advanced non-squamous non-small-cell lung cancer (PARAMOUNT): a double-blind, phase 3, randomised controlled trial.
    Paz-Ares L; de Marinis F; Dediu M; Thomas M; Pujol JL; Bidoli P; Molinier O; Sahoo TP; Laack E; Reck M; Corral J; Melemed S; John W; Chouaki N; Zimmermann AH; Visseren-Grul C; Gridelli C
    Lancet Oncol; 2012 Mar; 13(3):247-55. PubMed ID: 22341744
    [TBL] [Abstract][Full Text] [Related]  

  • 7. An Exploratory Randomized Phase II Trial Comparing CDDP Plus S-1 With Bevacizumab and CDDP Plus Pemetrexed With Bevacizumab Against Patients With Advanced Non-squamous Non-small Cell Lung Cancer.
    Kaira K; Imai H; Souma R; Sakurai R; Miura Y; Sunaga N; Kasahara N; Tsukagoshi Y; Koga Y; Kitahara S; Kotake M; Minato K; Naruse I; Fukushima Y; Hisada T; Ishizuka T
    Anticancer Res; 2019 May; 39(5):2483-2491. PubMed ID: 31092443
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Phase II trial of induction chemotherapy of pemetrexed plus split-dose cisplatin followed by pemetrexed maintenance for untreated non-squamous non-small-cell lung cancer.
    Koba T; Minami S; Nishijima-Futami Y; Masuhiro K; Kimura H; Futami S; Yaga M; Mori M; Kagawa H; Uenami T; Kohmo S; Otsuka T; Yamamoto S; Komuta K; Kijima T
    Cancer Chemother Pharmacol; 2018 Jul; 82(1):111-117. PubMed ID: 29728800
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Bevacizumab, Pemetrexed, and Cisplatin, or Bevacizumab and Erlotinib for Patients With Advanced Non-Small-Cell Lung Cancer Stratified by Epidermal Growth Factor Receptor Mutation: Phase II Trial SAKK19/09.
    Gautschi O; Mach N; Rothschild SI; Li Q; Stahel RA; Zippelius A; Cathomas R; Früh M; Betticher DC; Peters S; Rauch D; Feilchenfeldt J; Bubendorf L; Savic S; Jaggi R; Leibundgut EO; Largiadèr C; Brutsche M; Pilop C; Stalder L; Pless M; Ochsenbein AF;
    Clin Lung Cancer; 2015 Sep; 16(5):358-65. PubMed ID: 25843489
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Randomized phase III trial of maintenance bevacizumab with or without pemetrexed after first-line induction with bevacizumab, cisplatin, and pemetrexed in advanced nonsquamous non-small-cell lung cancer: AVAPERL (MO22089).
    Barlesi F; Scherpereel A; Rittmeyer A; Pazzola A; Ferrer Tur N; Kim JH; Ahn MJ; Aerts JG; Gorbunova V; Vikström A; Wong EK; Perez-Moreno P; Mitchell L; Groen HJ
    J Clin Oncol; 2013 Aug; 31(24):3004-11. PubMed ID: 23835708
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Phase II study of carboplatin and pemetrexed in advanced non-squamous, non-small-cell lung cancer: Kyoto Thoracic Oncology Research Group Trial 0902.
    Kim YH; Hirabayashi M; Togashi Y; Hirano K; Tomii K; Masago K; Kaneda T; Yoshimatsu H; Otsuka K; Mio T; Tomioka H; Suzuki Y; Mishima M
    Cancer Chemother Pharmacol; 2012 Aug; 70(2):271-6. PubMed ID: 22752216
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Pemetrexed/Carboplatin/Bevacizumab followed by Maintenance Pemetrexed/Bevacizumab in Hispanic Patients with Non-Squamous Non-Small Cell Lung Cancer: Outcomes according to Thymidylate Synthase Expression.
    Cardona AF; Rojas L; Wills B; Arrieta O; Carranza H; Vargas C; Otero J; Cuello M; Corrales L; Martín C; Ortiz C; Franco S; Rosell R;
    PLoS One; 2016; 11(5):e0154293. PubMed ID: 27191954
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Maintenance therapy with pemetrexed and bevacizumab versus pemetrexed monotherapy after induction therapy with carboplatin, pemetrexed, and bevacizumab in patients with advanced non-squamous non small cell lung cancer.
    Karayama M; Inui N; Fujisawa T; Enomoto N; Nakamura Y; Kuroishi S; Yokomura K; Koshimizu N; Sato M; Toyoshima M; Shirai T; Masuda M; Yamada T; Imokawa S; Suda T
    Eur J Cancer; 2016 May; 58():30-7. PubMed ID: 26922170
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Platinum-Vinorelbine Induction Chemotherapy plus Bevacizumab With and Without Pemetrexed Switch Maintenance in Advanced NSCLC.
    Michelsen L; Sørensen JB
    Anticancer Res; 2015 Nov; 35(11):6255-9. PubMed ID: 26504059
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Phase II Study of Carboplatin and Pemetrexed in Advanced EGFR-wild-type Non-squamous Non-small Cell Lung Cancer: The Central Japan Lung Study Group Trial 0906.
    Kimura T; Taniguchi H; Watanabe N; Saka H; Kogure Y; Shindo J; Ogasawara T; Kojima E; Hasegawa Y; Yamamoto M; Suzuki R; Ando M; Kondo M; Saito H
    Anticancer Res; 2016 Apr; 36(4):1767-71. PubMed ID: 27069157
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Feasibility Study of Sequentially Alternating EGFR-TKIs and Chemotherapy for Patients with Non-small Cell Lung Cancer.
    Takemura Y; Chihara Y; Morimoto Y; Tanimura K; Imabayashi T; Seko Y; Kaneko Y; Date K; Ueda M; Arimoto T; Iwasaki Y; Takayama K
    Anticancer Res; 2018 Apr; 38(4):2385-2390. PubMed ID: 29599365
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Sintilimab plus bevacizumab biosimilar IBI305 and chemotherapy for patients with EGFR-mutated non-squamous non-small-cell lung cancer who progressed on EGFR tyrosine-kinase inhibitor therapy (ORIENT-31): first interim results from a randomised, double-blind, multicentre, phase 3 trial.
    Lu S; Wu L; Jian H; Chen Y; Wang Q; Fang J; Wang Z; Hu Y; Sun M; Han L; Miao L; Ding C; Cui J; Li B; Pan Y; Li X; Ye F; Liu A; Wang K; Cang S; Zhou H; Sun X; Ferry D; Lin Y; Wang S; Zhang W; Zhang C
    Lancet Oncol; 2022 Sep; 23(9):1167-1179. PubMed ID: 35908558
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Phase II study of bevacizumab, cisplatin, and pemetrexed in advanced non-squamous non-small cell lung cancer (NS-NSCLC) with EGFR wild-type.
    Murakami S; Saito H; Kondo T; Oshita F; Yamada K
    J Exp Ther Oncol; 2019 Dec; 13(2):131-138. PubMed ID: 31881129
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Phase II study of pemetrexed and carboplatin plus bevacizumab with maintenance pemetrexed and bevacizumab as first-line therapy for nonsquamous non-small-cell lung cancer.
    Patel JD; Hensing TA; Rademaker A; Hart EM; Blum MG; Milton DT; Bonomi PD
    J Clin Oncol; 2009 Jul; 27(20):3284-9. PubMed ID: 19433684
    [TBL] [Abstract][Full Text] [Related]  

  • 20. A phase IB dose-escalation study of the safety and pharmacokinetics of pictilisib in combination with either paclitaxel and carboplatin (with or without bevacizumab) or pemetrexed and cisplatin (with or without bevacizumab) in patients with advanced non-small cell lung cancer.
    Soria JC; Adjei AA; Bahleda R; Besse B; Ferte C; Planchard D; Zhou J; Ware J; Morrissey K; Shankar G; Lin W; Schutzman JL; Dy GK; Groen HJM
    Eur J Cancer; 2017 Nov; 86():186-196. PubMed ID: 28992562
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 28.